Towards new broader spectrum pneumococcal vaccines: The future of Pneumococcal disease prevention

Academic Article


  • Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines. © 2014 by the authors; licensee MDPI, Basel, Switzerland.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Lee LH; Gu XX; Nahm MH
  • Start Page

  • 112
  • End Page

  • 128
  • Volume

  • 2
  • Issue

  • 1